DEventer-ALkmaar Heart failure Project.
Completed
- Registration Number
- NL-OMON24472
- Lead Sponsor
- Funding/Support: This study was financially supported by a grant from Novartis Pharma BV, AstraZeneca BV, Bristol-Myers Squibb BV. Roche Diagnostics provided the test essays for NT-proBNP.Role of sponsors: The funding source for this study played no role in the design or conduct of the study; data management and analysis; or manuscript preparation, review, and authorisation for submission.
- Brief Summary
Bruggink-Andre de la Porte PW, Lok DJ, van Wijngaarden J, Cornel JH, Pruijsers-Lamers D, van Veldhuisen DJ, Hoes AW. Related Articles, Links.<br> Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study.<br> Eur J Heart Fail. 2005 Aug;7(5):910-20. Review. <br> PMID: 16087143 [PubMed - indexed for MEDLINE].
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 240
Inclusion Criteria
The following are required at screening visit:
1. In – or out hospital patients with congestive heart failure New York Heart Association Functional Class III and IV;
Exclusion Criteria
1. Severe dementia or serious psychiatric illness;
2. Discharge to a nursing home;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint was the composite of hospitalisation for worsening HF and/or all cause mortality. Further, the effect on LVEF, NYHA class, quality of life, NT-proBNP, and self-care behaviour was assessed.
- Secondary Outcome Measures
Name Time Method Additional endpoints included time to (HF) hospitalization or death, utilisation of HF medication and costs of care.